leisure time -WSS

leisure time

author：fashion 2025-09-30 06:09:18 - browse：987

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Obamacare plans could cover weight loss drugs

explore

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Weight loss drugs aren’t covered by Obamacare. That may change

Reporting on presidential health from Reagan to Trump and Biden

Take antibiotics after sex, CDC recommends for certain risk groups

Wikipedia

leisure time

explore

Medical leaders decry Supreme Court decision on affirmative action

Secretariat’s lessons for human medicine

Novavax promises a turnaround & Lilly roils the obesity market

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

23andMe had bad news about my health. I wish a person had delivered it

Structure Therapeutics oral GLP

The high cost of giving birth even with insurance

STAT wants to know your pick for a great summer read or listen

Trump demands the U.S. pay no more for drugs than other countries … again

A new initiative will help leaders fight the next pandemic

Wikipedia

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Fight over Supreme Court dialysis ruling puts kidney patients at risk

CMS got Medicare Advantage quality rating wrong, judge rules

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Medicare Advantage's lean provider networks lead CMS complaints

Take antibiotics after sex, CDC recommends for certain risk groups

explore

hotspot

explore

knowledge